WaveMan
WaveMan · SEC 13F
Foresite Capital Management IV, LLC 13F holdings
> Search tickers & screens ⌘K
LIVE

Foresite Capital Management IV, LLC 13F holdings

Foresite Capital Management IV, LLC reported 6 positions with a total reported value of $290.2M as of 2026-06-30, in its 13F for Q2 2026, filed 2026-08-14. Top holdings by reported value: PHVS Pharvaris N.V. (57.0%), CYTK CYTOKINETICS INC (21.0%), EIKN Eikon Therapeutics, Inc. (8.7%), RLAY Relay Therapeutics, Inc. (8.1%), XENE Xenon Pharmaceuticals Inc. (3.3%). Against 2026-03-31 it opened 1 new position and exited 3. Next 13F due by 2026-11-14, the legal deadline 45 days after the quarter ending 2026-09-30.

Email me when Foresite Capital Management IV, LLC files its 13F

A free account follows up to 10 funds. New 13F filings arrive in your daily or weekly digest. No password and no card.

Top holdings

6 largest of 6 positions · reported value as of 2026-06-30
HoldingSharesReported value% of portfolio
PHVS Pharvaris N.V.4,778,581$165.2M57.0%
CYTK CYTOKINETICS INC714,695$60.9M21.0%
EIKN Eikon Therapeutics, Inc.1,943,682$25.4M8.7%
RLAY Relay Therapeutics, Inc.1,250,000$23.4M8.1%
XENE Xenon Pharmaceuticals Inc.160,000$9.7M3.3%
CRNX Crinetics Pharmaceuticals, Inc.150,000$5.6M1.9%
SEC FORM 13F · Q2 2026 · VALUES AS REPORTED, NOT PRICES

New positions this quarter

Held at 2026-06-30, not at 2026-03-31 · 1 in all · reported value as of 2026-06-30
HoldingSharesReported value% of portfolio
CRNX Crinetics Pharmaceuticals, Inc.150,000$5.6M1.9%

Sold out

Held at 2026-03-31, gone by 2026-06-30 · 3 in all · reported value as of 2026-03-31
HoldingShares 2026-03-31Reported value% of portfolio then
LYEL Lyell Immunopharma, Inc.800,399$16.1M6.8%
ALEC Alector, Inc.3,887,200$8.4M3.5%
MAZE Maze Therapeutics, Inc.156,901$4.7M2.0%

Biggest increases and decreases

Positions held at both quarter ends, by change in shares · reported value as of 2026-06-30

Increases

HoldingShares 2026-03-31Shares 2026-06-30ChangeReported value
CYTK CYTOKINETICS INC503,295714,695+42.0%$60.9M
RLAY Relay Therapeutics, Inc.1,000,0001,250,000+25.0%$23.4M

Decreases

No position was decreased.

CIK 1704132 · 13F FILINGS ON EDGAR · INFORMATIONAL ONLY

Source: U.S. Securities and Exchange Commission (EDGAR) and other official government data · Updated 2026-10-28 · For informational purposes only, not investment advice.
Privacy · Terms